Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR168 in Refractory Autoimmune Diseases
NCT06249438Phase 1Recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C-CAR168 in systemic lupus erythematosus (SLE), immune-mediated necrotizing myopathy (IMNM), Neuromyelitis Optica Spectrum Disorder (NMOSD) and 3 more, sponsored by Renji Hospital. Primary endpoints: Incidence of Adverse Events [Safety and Tolerability] at 24 months and The subsequent recommended dose of C-CAR168 at 24 months. Started Mar 2024; status: recruiting.
02
Drugs
C-CAR168
03
Conditions
systemic lupus erythematosus (SLE)immune-mediated necrotizing myopathy (IMNM)Neuromyelitis Optica Spectrum Disorder (NMOSD)multiple sclerosis (MS)myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06249438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249438.